循环肿瘤细胞和DNA用于非小细胞肺癌表皮生长因子受体的实时检测与监测
Circulating tumor cells and DNA for real-time EGFR detection and monitoring of non-small-cell lung cancer.
作者信息
He Jinfeng, Tan Wei, Ma Jingping
机构信息
Department of Respiratory Medicine, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, People's Republic of China.
Haemodialysis Centre, Jingzhou Central Hospital, The Second Clinical Medical College, Yangtze University, Jingzhou, People's Republic of China.
出版信息
Future Oncol. 2017 Apr;13(9):787-797. doi: 10.2217/fon-2016-0427. Epub 2017 Jan 11.
AIM
We investigate the suitability of circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in non-small-cell lung cancer management, which is challenging in conventional biopsies.
MATERIALS & METHODS: We performed serial blood extraction from 120 patients of varying EGFR status. Molecular profiling was performed using droplet digital PCR and correlated to survival outcome.
RESULTS
Overall, we observed 95% agreement using CTCs and ctDNA with conventional tissue biopsies, which indicated the disease's close correlation. The mutant signature was stable and captured the dynamic changes during treatment. It aided to stratify patients with worse survival outcome.
CONCLUSION
CTCs and ctDNA can complement current disease management. We demonstrated its effectiveness in continuous disease profiling, which is critical for clinical decision-making.
目的
我们研究循环肿瘤细胞（CTCs）和循环肿瘤DNA（ctDNA）在非小细胞肺癌管理中的适用性，这在传统活检中具有挑战性。
材料与方法
我们对120例不同表皮生长因子受体（EGFR）状态的患者进行了系列血液采集。使用液滴数字PCR进行分子分析，并与生存结果相关联。
结果
总体而言，我们观察到CTCs和ctDNA与传统组织活检的一致性达95%，这表明疾病之间存在密切关联。突变特征是稳定的，并捕捉到了治疗期间的动态变化。它有助于对生存结果较差的患者进行分层。
结论
CTCs和ctDNA可以补充当前的疾病管理。我们证明了其在连续疾病分析中的有效性，这对临床决策至关重要。
Zotero 插件